Basilea names new member of its Extended Management Committee

ID: 1477898
recent pressrelease next pressrelease

(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea names new member of its Extended Management Committee
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced that, as of January 1, 2017, Ursula Eberhardt will take the role of
Head of Global Human Resources and join the Extended Management Committee which
reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who
retires as of December 31, 2016. Ms. Eberhardt has served in various positions
in Basilea''s Corporate Department and Human Resources team since joining Basilea
in 2006 and most recently was deputy Head of Global Human Resources.

Ronald Scott, Basilea''s Chief Executive Officer, indicated: "Basilea greatly
appreciates Ms. McDaid who built Basilea''s human resources department and
operations from our founding to a level of industry excellence. Basilea''s human
resources activities will continue to be in good hands under Ms. Eberhardt, who
has been our deputy Head of Global Human Resources for the last seven years. We
wish Ms. McDaid all the best in her retirement and much success to Ms. Eberhardt
in her new position."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment options
in the therapeutic areas of bacterial infections, fungal infections and cancer.
The company uses the integrated research, development and commercial operations
of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop
and commercialize innovative pharmaceutical products to meet the medical needs
of patients with serious and potentially life-threatening conditions. Basilea
Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX

Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea''s


This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

| Peer Nils Schröder, PhD |
| Head of Corporate Communications & Investor Relations |
| +41 61 606 1102 |
| media_relations(at) |
| investor_relations(at) |

This press release can be downloaded from

Press release (PDF):

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via GlobeNewswire

More information: http://www.marketresearchhub.

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 12/29/2016 - 01:15
Language: English
News-ID 1477898
Character count: 3565
Firma: Basilea Pharmaceutica AG
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Basel


Number of hits: 295


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 80

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.